Cogent Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $5.13B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 2, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 17, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 3, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 10, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 25, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | – | $-0.59 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | Before market open | – | $-0.62 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 26, 2024 | Before market open | – | $-0.63 | – |
Press releases
Announcements Cogent Biosciences filed with the SEC
Cogent Biosciences Reports Recent Business Highlights and
Results of operations · EX-99.1 to Form 8-K
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Cogent Biosciences Reports Recent Business Highlights and
Results of operations · EX-99.1 to Form 8-K
Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625%
Material agreement · Other events · EX-99.1 to Form 8-K
Stromal Tumors (GIST) Top-Line Results Investor Webcast November 10, 2025
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cogent Biosciences Reports Recent Business Highlights and
Results of operations · EX-99.1 to Form 8-K
Cogent Biosciences Reports Recent Business Highlights and
Results of operations · EX-99.1 to Form 8-K
Cogent Biosciences Announces Positive Top-line Results Achieving
Material agreement · Results of operations · EX-99.1 to Form 8-K
Cogent Biosciences Secures up to $400 Million in Non-Dilutive
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
this presentation has been prepared by Cogent Biosciences, Inc. (“Cogent” or the “Company”) and contains information pertaining to the business and operations of the Company. The information contained in this presentation:
Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Cogent Biosciences Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Cogent Biosciences Reports Recent Business Highlights and
Results of operations · EX-99.1 to Form 8-K
Cogent Biosciences Reports Recent Business Highlights and
Results of operations · EX-99.1 to Form 8-K
Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal
Other events · EX-99.1 to Form 8-K
Cogent Biosciences Reports Recent Business Highlights and
Results of operations · EX-99.1 to Form 8-K
Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel
Other events · EX-99.1 to Form 8-K
Cogent Biosciences Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Cogent Biosciences Reports Recent Business Highlights and
Results of operations · EX-99.1 to Form 8-K
Cogent Biosciences Reports Recent Business Highlights and
Results of operations · EX-99.1 to Form 8-K
Cogent Biosciences Reports Recent Business Highlights and First Quarter
Results of operations · EX-99 to Form 8-K
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99 to Form 8-K
Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX
Regulation FD disclosure · EX-99.1 to Form 8-K
Bezuclastinib in Advanced Systemic Mastocytosis Investor Webcast December 12, 2022 Presented at American Society of Hematology Conference December 11, 2022
Regulation FD disclosure · EX-99.2 to Form 8-K
Cogent Biosciences Reports Recent Business Highlights and
Results of operations · EX-99.1 to Form 8-K
Cogent Biosciences Reports Recent Business Highlights and
Results of operations · EX-99.1 to Form 8-K
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Pre-funded Warrants
Material agreement · Other events · EX-99.1 to Form 8-K/A
Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating
Shareholder vote results · Other events · EX-99.1 to Form 8-K
Advanced Systemic Mastocytosis Investor Webcast Presented at the European Hematology Association Congress June 10, 2022
Shareholder vote results · Other events · EX-99.2 to Form 8-K
Cogent Biosciences Reports Recent Business Highlights and First Quarter
Results of operations · EX-99.1 to Form 8-K
Cogent Biosciences Provides Corporate Updates , Fourth Quarter
Results of operations · EX-99.1 to Form 8-K
Cogent Biosciences Provides Corporate Updates and
Results of operations · EX-99.1 to Form 8-K